[{"indications": "Indications\u00a0\n(From 3.3.3 Phosphodiesterase type-4 inhibitors: British National Formulary)\n3.3.3 Phosphodiesterase type-4 inhibitors", "name": "ROFLUMILAST", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.3 Cromoglicate\r\nand related therapy, leukotriene receptor antagonists, and phosphodiesterase\r\ntype-4 inhibitors", "3.3.3 Phosphodiesterase type-4 inhibitors"], "cautions": "Cautions\u00a0monitor body-weight; latent infection (such as tuberculosis, viral hepatitis, herpes infection); moderate\r\nto severe cardiac failure; history of psychiatric\r\nillness, or concomitant use of drugs likely\r\nto cause psychiatric events; interactions: Appendix 1 (roflumilast)", "side-effects": "Side-effects\u00a0diarrhoea, nausea, abdominal pain, weight loss,\r\ndecreased appetite, headache, insomnia; less commonly gastritis, vomiting, gastro-oesophageal reflux, dyspepsia, palpitation,\r\nanxiety, tremor, vertigo, dizziness, malaise, muscle spasm, myalgia,\r\nback pain, rash; rarely taste disturbances, haematochezia,\r\nconstipation, respiratory tract infections, depression, nervousness,\r\nsuicidal ideation, gynaecomastia, raised creatine kinase, urticaria", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/211005.htm", "doses": ["adult over 18 years, 500\u00a0micrograms\r\nonce daily"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid\u2014toxicity in animal studies; women of child-bearing age should use effective contraception "}]